Light therapy and fluvoxamine in the treatment of bipolar psychotic depression: A pilot study

Clinical Neuropsychiatry

Volumn 6, Issue 4, 2009, Pages 166-173

  Franchini, Linda ^a   Ballan, Simone ^a   Colombo, Cristina ^a   Smeraldi, Enrico ^a  

^a NONE

Author keywords

Bipolar disorder; Fluvoxamine; Light therapy; Psychotic depression

Indexed keywords

FLURAZEPAM; FLUVOXAMINE; LITHIUM;

ADULT; AGED; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR MANIA; CHRONOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DEPRESSIVE PSYCHOSIS; DISEASE COURSE; DRUG DOSE TITRATION; FEMALE; HAMILTON SCALE; HUMAN; MALE; MONOTHERAPY; PHOTOTHERAPY; PILOT STUDY; REMISSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 74849105009     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS (2007). Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry 68, 194-200.
2. Benedetti F, Barbini B, Colombo C, Smeraldi E (2007). Chronotherapeutics in a psychiatric ward. Sleep Med Rev 11, 509-522.
3. Benedetti F, Colombo C, Pontiggia A, Bernasconi A, Florita M, Smeraldi E (2003). Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry 64, 648-653.
4. Benedetti F, Zanardi R, Colombo C, Smeraldi E (1999). Worsening of delusional depression after sleep deprivation: case reports. J Psychiatr Res 33, 69-72.
5. Bojkowski CJ, Aldhous ME, English J, Franey C, Poulton AL, Skene DJ, Arendt J (1987). Suppression of nocturnal plasma melatonin and 6-sulphatoxymelatonin by bright and dim light in man. Horm Metab Res 19, 437-440.
6. Cajochen C (2007). Alerting effects of light. Sleep Med Rev 11, 453-464.
7. Coryell W, Endicott J, Maser JD, Keller MB, Leon AC, Akiskal HS (1995). Long-term stability of polarity distinctions in the affective disorders. Am J Psychiatry 152, 385-390.
8. Demisch K, Demisch L, Bochnik HJ, Nickelsen T, Althoff PH, Schoffling K, Rieth R (1986). Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol 22, 620-622.
9. Demisch K, Demisch L, Nickelsen T, Rieth R (1987). The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increases following fluvoxamine. J Neural Transm 68, 257-270.
10. Elsenga S, Beersma D, Van den Hoofdakker RH (1990). Total and partial sleep deprivation in clomipramine-treated endogenous depressives. J Psychiatr Res 24, 111-119.
11. Elsenga S, Van den Hoofdakker RH (1987). Response to total sleep deprivation and clomipramine in endogenous depression. J Psychiatr Res 21, 151-161.
12. Fahndrich E (1981). Effects of sleep deprivation on depressed patients of different nosological groups. Psychiatty Res 5, 277-285.
13. Frazer A, Brown R, Kocsis J, Caroff S, Amsterdam J, Winokur A, Sweeney J, Stokes P (1986). Patterns of melatonin rhythms in depression. J Neural Transm Suppl 21, 269-290.
14. Gatti F, Bellini L, Gasperini M, Perez J, Zanardi R, Smeraldi E (1996). Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 153, 414-416.
15. Gaudiano BA, Young D, Chelminski I, Zimmerman M (2008). Depressive symptom profiles and severity patterns in outpatients with psychotic vs nonpsychotic major depression. Compr Psychiatry 49, 421-429.
16. Glassman AH, Roose SP (1981). Delusional depression. A distinct clinical entity? Arch Gen Psychiatry 38, 424-427.
17. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23, 56-62.
18. Hartter S, Wang X, Weigmann H, Friedberg T, Arand M, Oesch F, Hiemke C (2001). Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 21, 167-174.
19. Hashimoto K (2009) Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Central Nervous System Agents in medicinal chemistry in press.
20. Hayashi T, Stahl SM (2009) The sigma-1 receptor and its role in the treatement of mood disorders. Drugs of the Future 3, 2 137-146
21. Holsboer-Trachsler E (1994). [Monitoring the neurobiological and psychopathological course in therapy of depression. Trimipramine, sleep deprivation and light]. Bibl Psychiatr 1-138.
22. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V (1994). Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment - neurobiological and psychometric assessment of course. J Psychiatr Res 28, 381-399.
23. Horne JA, Ostberg O (1976). A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 4, 97-110.
24. Keller J, Schatzberg AF, Maj M (2007). Current issues in the classification of psychotic major depression. Schizophr Bull 33, 877-885.
25. Kendler KS, Glazer WM, Morgenstern H (1983). Dimensions of delusional experience. Am J Psychiatry 140, 466-469.
26. King D, Dowdy S, Jack R, Gardner R, Edwards P (1982). The dexamethasone suppression test as a predictor of sleep deprivation antidepressant effect. Psychiatry Res 7, 93-99.
27. Kripke DF (1998). Light treatment for nonseasonal depression: speed, efficacy, and combined treatment. J Affect Disord 49, 109-117.
28. Labbate LA, Lafer B, Thibault A, Sachs GS (1994). Side effects induced by bright light treatment for seasonal affective disorder. J Clin Psychiatiy 55, 189-191.
29. Levitt AJ, Joffe RT, Kennedy SH (1991). Bright light augmentation in antidepressant nonresponders. J Clin Psychiatry 52, 336-337.
30. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP (1980). Light suppresses melatonin secretion in humans. Science 210, 1267-1269.
31. Mackert A, Volz HP, Stieglitz RD, Muller-Oerlinghausen B (1991). Phototherapy in nonseasonal depression. Biol Psychiatry 30, 257-268.
32. Martiny K (2004). Adjunctive bright light in non-seasonal major depression. Acta Psychiatr Scand Suppl, 7-28.
33. Martiny K, Lunde M, Unden M, Dam H, Bech P (2005a). Adjunctive bright light in non-seasonal major depression: results from clinician-rated depression scales. Acta Psychiatr Scand 112, 117-125.
34. Martiny K, Lunde M, Unden M, Dam H, Bech P (2005b). Adjunctive bright light in non-seasonal major depression: results from patient-reported symptom and well-being scales. Acta Psychiatr Scand 111, 453-459.
35. Mitchell PB, Malhi GS (2004). Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord 6, 530-539.
36. Mitchell PB, Wilhelm K, Parker G, Austin MP, Rutgers P, Malhi GS (2001). The clinical features of bipolar depression: a comparison with matched major depressive disorder patients. J Clin Psychiatry 62, 212-216; quiz 217.
37. Plenge P, Mellerup ET (2003). Pindolol and the acceleration of the antidepressant response. J Affect Disord 75, 285-289
38. Prasko J, Foldmann P, Praskova H, Zindr V (1988). [Hastening the onset of the effect of antidepressive agents during the use of 3 different time periods of exposure to intensive white light]. Cesk Psychiatr 84, 374-383.
39. Prasko J, Horacek J, Klaschka J, Kosova J, Ondrackova I, Sipek J (2002). Bright light therapy and/or imipramine for inpatients with recurrent non-seasonal depression. Neuro Endocrinol Lett 23, 109-113.
40. Rothschild AJ (1996). Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 19, 237-252.
41. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT (1993). Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry 54, 338-342.
42. Serretti A, Lattuada E, Smeraldi E (1999). Outcome of affective psychosis. Depress Anxiety 10, 50-54.
43. Serretti A, Lattuada E, Zanardi R, Franchini L, Smeraldi E (2000). Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Res 94, 185-190.
44. Skene DJ, Arendt J (2006). Human circadian rhythms: physiological and therapeutic relevance of light and melatonin. Ann Clin Biochem 43, 344-353.
45. Skene DJ, Bojkowski CJ, Arendt J (1994). Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 37, 181-186.
46. Stahl SM (2005). Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. CNS Spectr 10, 319-323.
47. Stanley M, Brown GM (1988). Melatonin levels are reduced in the pineal glands of suicide victims. Psychopharmacol Bull 24, 484-488.
48. Terman M (2007). Evolving applications of light therapy. Sleep Med Rev 11, 497-507.
49. Thompson C, Franey C, Arendt J, Checkley SA (1988). A comparison of melatonin secretion in depressed patients and normal subjects. Br J Psychiatry 152, 260-265.
50. Vandewalle G, Balteau E, Phillips C, Degueldre C, Moreau V, Sterpenich V, Albouy G, Darsaud A, Desseilles M, Dang-Vu TT, Peigneux P, Luxen A, Dijk DJ, Maquet P (2006). Daytime light exposure dynamically enhances brain responses. Curr Biol 16, 1616-1621.
51. Wijkstra J, Lijmer J, Balk F, Geddes J, Nolen WA (2005). Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev CD004044.
52. Wirz-Justice A (2008). Diurnal variation of depressive symptoms. Dialogues Clin Neurosci 10, 3, 337-343.
53. Wirz-Justice A, Benedetti F, Berger M, Lam RW, Martiny K, Terman M, Wu JC (2005). Chronotherapeutics (light and wake therapy) in affective disorders. Psychol Med 35, 939-944.
54. Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I (1995). Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry 28, 56-60.
55. Zanardi R, Franchini L, Gasperini M, Lucca A, Smeraldi E, Perez J (1998). Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J Clin Psychopharmacol 18, 441-446.
56. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E (2001). Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 50, 323-330.
57. Zee PC, Manthena P (2007). The brain's master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev 11, 59-70.
58. Zihl J, von Cramon D (1979). The contribution of the 'second' visual system to directed visual attention in man. Brain 102, 835-856.